Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project
Launched by UNIVERSITY OF ULM · Dec 2, 2010
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
The BiO-Project is a clinical trial that aims to understand more about acute myeloid leukemia (AML) and certain related blood disorders, including higher risk myelodysplastic syndromes (MDS). This study will involve adults who have recently been diagnosed with these conditions or have had them return after treatment. Researchers will collect information about the patients, including their medical history and genetic markers, and will track their health outcomes over a maximum of 10 years. They will also store biological samples, like blood and tissue, to help with future research.
To participate in this study, individuals must be at least 18 years old and have a suspected diagnosis of AML or related conditions. Participants will need to give their consent to share their information and samples. Throughout the study, participants can expect regular follow-ups and assessments to monitor their disease and quality of life. This research is being conducted at multiple sites in Germany and Austria and aims to improve understanding and treatment options for these serious blood disorders.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with suspected diagnosis of acute myeloid leukemia and related neoplasms, newly diagnosed or relapsed/refractory, classified according to the International Consensus Classification
- • Age ≥ 18 years. There is no upper age limit.
- • Signed written informed consent
- Exclusion Criteria:
- • Severe neurological or psychiatric disorder interfering with ability to give an informed consent
- • No consent for registration, storage and processing of the individual patient and disease characteristics and course as well as information of the family physician about study participation
- • No consent for biobanking of patient's biological specimens and performance of analyses on stored material.
About University Of Ulm
The University of Ulm is a leading academic institution located in Germany, renowned for its commitment to cutting-edge research and innovation in the fields of medicine and health sciences. As a clinical trial sponsor, the university leverages its robust network of researchers and clinical experts to advance medical knowledge and improve patient outcomes. With a focus on interdisciplinary collaboration, the University of Ulm conducts comprehensive clinical studies that adhere to the highest ethical standards and regulatory guidelines. Through its research initiatives, the university aims to contribute significantly to the development of new therapies and treatment modalities, fostering a deeper understanding of various health conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hamburg, , Germany
Augsburg, , Germany
Hannover, , Germany
Berlin, , Germany
Augsburg, , Germany
München, , Germany
Traunstein, , Germany
Düsseldorf, , Germany
Bad Saarow, , Germany
Minden, , Germany
Passau, , Germany
Landshut, , Germany
Karlsruhe, , Germany
Oldenburg, , Germany
Hamburg, , Germany
Bremen, , Germany
Stuttgart, , Germany
Bonn, , Germany
Graz, , Austria
Innsbruck, , Austria
Lebach, , Germany
Göttingen, , Germany
Ludwigshafen, , Germany
Darmstadt, , Germany
Braunschweig, , Germany
Ulm, , Germany
Oldenburg, , Germany
Wien, , Austria
Freiburg, , Germany
Hamm, , Germany
Hanau, , Germany
Hannover, , Germany
Heilbronn, , Germany
Lemgo, , Germany
Trier, , Germany
Wuppertal, , Germany
Homburg/Saar, , Germany
Magdeburg, , Germany
Esslingen, , Germany
Lüdenscheid, , Germany
Dortmund, , Germany
Aurich, , Germany
Flensburg, , Germany
München, , Germany
Karlsruhe, , Germany
Linz, , Austria
Linz, , Austria
Linz, , Austria
Rankweil, , Austria
Salzburg, , Austria
Aschaffenburg, , Germany
Berlin, , Germany
Berlin, , Germany
Berlin, , Germany
Bochum, , Germany
Düsseldorf, , Germany
Essen, , Germany
Frankfurt, , Germany
Fulda, , Germany
Gießen, , Germany
Goch, , Germany
Greifswald, , Germany
Göppingen, , Germany
Hamburg, , Germany
Herne, , Germany
Kaiserslautern, , Germany
Kiel, , Germany
Krefeld, , Germany
Lübeck, , Germany
Magdeburg, , Germany
Mainz, , Germany
Meschede, , Germany
Mutlangen, , Germany
Mühlheim, , Germany
Neuss, , Germany
Offenburg, , Germany
Recklinghausen, , Germany
Regensburg, , Germany
Saarbrücken, , Germany
Saarlouis, , Germany
Sande, , Germany
Stuttgart, , Germany
Stuttgart, , Germany
Trier, , Germany
Tübingen, , Germany
Ulm, , Germany
Villingen Schwenningen, , Germany
Offenbach, , Germany
Wernigerode, , Germany
Bochum, , Germany
Potsdam, , Germany
Salzburg, , Austria
Patients applied
Trial Officials
Hartmut Döhner, Prof. Dr.
Study Chair
University Hospital of Ulm
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials